Goldenwell Biotech, Inc.
GWLL
$0.77
-$0.13-14.44%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -349.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -349.60% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -1,048.80% | |||
| SG&A Expenses | 226.04% | -68.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -83.02% | 496.44% | |||
| Operating Income | 87.32% | -4,083.05% | |||
| Income Before Tax | 92.93% | -3,011.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 92.93% | -3,011.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 92.93% | -3,011.25% | |||
| EBIT | 87.32% | -4,083.05% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 91.30% | -2,200.00% | |||
| Normalized Basic EPS | 86.67% | -1,400.00% | |||
| EPS Diluted | 91.30% | -2,200.00% | |||
| Normalized Diluted EPS | 86.67% | -1,400.00% | |||
| Average Basic Shares Outstanding | -7.22% | 10.65% | |||
| Average Diluted Shares Outstanding | -7.22% | 10.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||